Efficacy and safety of fecal microbiota transplantation in children with refractory functional abdominal pain disorders: an open-label pilot trial with exploratory microbiome analyses

Abstract Background Fecal microbiota transplantation (FMT) rebuilds the gut microbiota, yet its efficacy in pediatric refractory functional abdominal pain disorders (FAPDs) is insufficiently described. The purpose of this study is to identify gut microbiota dysbiosis in pediatric FAPDs and to examine the effectiveness, safety, and microbial biomarkers of FMT in these patients. Methods In a two-phase study, gut microbiota (16 S rRNA sequencing) were compared between 47 children with FAPDs and 39 healthy controls. Thereafter, a non-randomized, open-label prospective pilot trial (ClinicalTrials.gov: NCT05753774) allocated the 47 refractory patients, according to guardian and/or patient preference, to receive FMT plus conventional therapy ( n = 26) or conventional therapy only ( n = 21). The trial was terminated early because of slow recruitment (47 of 50 planned participants). The primary endpoint was the composite response rate at weeks 4 and 8. Results At baseline, patients had significant gut microbiota dysbiosis: 3.5-fold Proteobacteria enrichment (20.6% vs. 5.8%; P < 0.001), 4.1-fold Escherichia–Shigella expansion (12.7% vs. 3.1%; P < 0.001), and reduced α-diversity (Shannon index 4.7 ± 1.1 vs. 5.4 ± 1.1; P = 0.002). FMT plus conventional therapy was associated with a higher composite response rate at week 4 (69.2% vs. 14.3%; RR 4.85, 95% CI 1.65–14.24; Fisher’s exact P < 0.001) and week 8 (80.8% vs. 47.6%; RR 1.70, 95% CI 1.04–2.76; P = 0.029), with significantly better adjusted symptom scores in the FMT group at both time points. Post-FMT, Faecalibacterium and Blautia increased (+ 44.5% and + 99.1%), while Escherichia–Shigella declined (− 19.2%). Exploratory random forest models (seven genera for diagnosis; four genera characterizing the post-FMT, response-associated microbial signature) yielded internally validated AUCs of 0.896 (95% CI 0.821–0.952) and 0.890 (95% CI 0.699–1.000), respectively. FMT showed favorable short-term tolerability, with transient constipation in 50.0% of patients and no severe adverse events. Conclusions In this open-label pilot trial, FMT plus conventional therapy was associated with higher short-term response rates that were maintained through week 8 in children with refractory FAPDs. Exploratory microbial signatures further demonstrated potential for both diagnosis and characterization of the post-treatment, response-associated microbial state, and pending external validation. Trial registration: This study is registered at ClinicalTrials.gov on 11 February 2023 (registration number: NCT05753774), before the enrollment of the first participant. https://clinicaltrials.gov/study/NCT05753774

Authors

Institutions

Publication Details

Journal
European journal of medical research
Published
2026-11-14
DOI
https://doi.org/10.1186/s40001-026-05475-6
Primary Topic
Gastrointestinal motility and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and safety of fecal microbiota transplantation in children with refractory functional abdominal pain disorders: an open-label pilot trial with exploratory microbiome analyses

Biao Zou, Zhihua Huang, Yuqin Wang, Xuesong Li et al.
1 links
European journal of medical research
Gastrointestinal motility and disorders
article

Efficacy and safety of fecal microbiota transplantation in children with refractory functional abdominal pain disorders: an open-label pilot trial with exploratory microbiome analyses

Biao Zou, Zhihua Huang, Yuqin Wang, Xuesong Li, Shan Huang, Sainan Shu, Jiayi He, Chen Dong, Mengling Ruan, Shengxuan Liu1
article en

Abstract

Abstract Background Fecal microbiota transplantation (FMT) rebuilds the gut microbiota, yet its efficacy in pediatric refractory functional abdominal pain disorders (FAPDs) is insufficiently described. The purpose of this study is to identify gut microbiota dysbiosis in pediatric FAPDs and to examine the effectiveness, safety, and microbial biomarkers of FMT in these patients. Methods In a two-phase study, gut microbiota (16 S rRNA sequencing) were compared between 47 children with FAPDs and 39 healthy controls. Thereafter, a non-randomized, open-label prospective pilot trial (ClinicalTrials.gov: NCT05753774) allocated the 47 refractory patients, according to guardian and/or patient preference, to receive FMT plus conventional therapy ( n = 26) or conventional therapy only ( n = 21). The trial was terminated early because of slow recruitment (47 of 50 planned participants). The primary endpoint was the composite response rate at weeks 4 and 8. Results At baseline, patients had significant gut microbiota dysbiosis: 3.5-fold Proteobacteria enrichment (20.6% vs. 5.8%; P < 0.001), 4.1-fold Escherichia–Shigella expansion (12.7% vs. 3.1%; P < 0.001), and reduced α-diversity (Shannon index 4.7 ± 1.1 vs. 5.4 ± 1.1; P = 0.002). FMT plus conventional therapy was associated with a higher composite response rate at week 4 (69.2% vs. 14.3%; RR 4.85, 95% CI 1.65–14.24; Fisher’s exact P < 0.001) and week 8 (80.8% vs. 47.6%; RR 1.70, 95% CI 1.04–2.76; P = 0.029), with significantly better adjusted symptom scores in the FMT group at both time points. Post-FMT, Faecalibacterium and Blautia increased (+ 44.5% and + 99.1%), while Escherichia–Shigella declined (− 19.2%). Exploratory random forest models (seven genera for diagnosis; four genera characterizing the post-FMT, response-associated microbial signature) yielded internally validated AUCs of 0.896 (95% CI 0.821–0.952) and 0.890 (95% CI 0.699–1.000), respectively. FMT showed favorable short-term tolerability, with transient constipation in 50.0% of patients and no severe adverse events. Conclusions In this open-label pilot trial, FMT plus conventional therapy was associated with higher short-term response rates that were maintained through week 8 in children with refractory FAPDs. Exploratory microbial signatures further demonstrated potential for both diagnosis and characterization of the post-treatment, response-associated microbial state, and pending external validation. Trial registration: This study is registered at ClinicalTrials.gov on 11 February 2023 (registration number: NCT05753774), before the enrollment of the first participant. https://clinicaltrials.gov/study/NCT05753774

European journal of medical research
Huazhong University of Science and Technology (CN)
Good health and well-being
Gastrointestinal motility and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon